²é¿´: 366  |  »Ø¸´: 2

ÔỨ¹«×Ó

Ìú¸Ëľ³æ (ÖøÃûдÊÖ)

General

[ÇóÖú] ÇóÈüÀ´Îô²¼£¨Celecoxibum£©ÔÚUSP36ÒÔÉϵÄÖÊÁ¿±ê×¼ ÒÑÓÐ1È˲ÎÓë

¸÷λ´óϺ£¬½ô¼±ÇóÖúCelecoxibumµÄ×îÐÂÖÊÁ¿±ê×¼£¬×îºÃÊǽºÄÒ»òÖÆ¼ÁµÄ£¬Ô­ÁϵÄEP7.5ºÍUSP35µÄ±ê×¼ÎÒ×Ô¼º¾ÍÓУ¬USP36µÄûÓУ¬Çó¸÷λ°ï棡~
»Ø¸´´ËÂ¥
½ðľˮ»ðÍÁöÎÉ­íµì͈?
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

kobeyy

½ð³æ (ÕýʽдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
ÔỨ¹«×Ó: ½ð±Ò+10, ¡ï¡ï¡ïºÜÓаïÖú, лл 2013-12-31 12:17:46
Celecoxib
(sel'' e kox' ib).

C17H14F3N3O2S 381.4
4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;     
p-[5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide     [169590-42-5].
DEFINITION
Celecoxib contains NLT 98.0% and NMT 102.0% of C17H14F3N3O2S, calculated on the anhydrous basis.
IDENTIFICATION
  A. Infrared Absorption 197: [Note??Methods 197A, 197K, or 197M under Infrared Absorption may be used. ]
[Note??If the spectra obtained show differences, dissolve the substance to be examined and the Reference Standard separately in isopropyl alcohol, evaporate to dryness, and record the new spectra. ]
  B. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.
ASSAY
  Procedure
Buffer:  2.7 g/L of monobasic potassium phosphate adjusted with phosphoric acid to a pH of 3.0 ?? 0.2
Mobile phase:  Methanol, acetonitrile, and Buffer (3:1:6)
Diluent:  Methanol and water (3:1)
System suitability solution:  0.5 mg/mL of USP Celecoxib RS and 2.4 ??/mL each of USP Celecoxib Related Compound A RS and USP Celecoxib Related Compound B RS in Diluent
Standard solution:  0.5 mg/mL of USP Celecoxib RS in Diluent
Sample solution:  0.5 mg/mL of Celecoxib in Diluent
Chromatographic system  
(See Chromatography 621, System Suitability.)
Mode:  LC
Detector:  UV 215 nm
Column:  4.6-mm ?? 25-cm; 5-?? packing L11
Column temperature:  60
Flow rate:  1.5 mL/min
Injection size:  25 L
Run time:  About 1.5 times the celecoxib peak elution
System suitability  
Samples:  System suitability solution and Standard solution
Suitability requirements  
Resolution:  NLT 1.8 between celecoxib related compound A and celecoxib and NLT 1.8 between celecoxib and celecoxib related compound B, System suitability solution
Relative standard deviation:  NMT 0.73%, Standard solution
Analysis  
Samples:  Standard solution and Sample solution
Calculate the percentage of C17H14F3N3O2S in the portion of Celecoxib taken:
Result = (rU/rS) ?? (CS/CU) ?? 100
rU = = peak response from the Sample solution

rS = = peak response from the Standard solution

CS = = concentration of the Standard solution (mg/mL)

CU = = concentration of the Sample solution (mg/mL)

Acceptance criteria:  98.0%?C102.0% on the anhydrous basis
IMPURITIES
Inorganic Impurities  
  Heavy Metals: NMT 20 ppm
Diluent:  Acetone and water (17:3)
Standard solution:  Dilute 1.0 mL of Standard Lead Solution, prepared as directed under Heavy Metals 231, Special Reagents, with Diluent to 20 mL.
Sample solution:  Dissolve 0.50 g of Celecoxib in 20 mL of Diluent.
Blank solution:  20 mL of Diluent
Analysis  
Samples:  Standard solution, Blank solution, and Sample solution
To each solution, add 2 mL of pH 3.5 Acetate Buffer, prepared as directed under Heavy Metals 231, Method I. Mix, and add to each solution 1.2 mL of thioacetamide?Cglycerin base TS. Mix immediately, and allow to stand for 2 min. Pass the solutions through a filter of 0.45-?? pore size. Compare the spots on the filters obtained from each of the solutions.
Acceptance criteria:  The brownish-black color of the spot resulting from the Sample solution is not more intense than that of the spot resulting from the Standard solution. The test is invalid if the Standard solution does not show a brownish-black color compared to the Blank solution.
  Residue on Ignition 281: NMT 0.2%, using a platinum crucible
Organic Impurities  
  Procedure
Buffer, Mobile phase, Diluent, System suitability solution, Sample solution, and Chromatographic system:  Proceed as directed in the Assay.
Standard solution:  0.5 ??/mL of USP Celecoxib RS in Diluent
System suitability  
Samples:  System suitability solution and Standard solution
Suitability requirements  
Resolution:  NLT 1.8 between celecoxib related compound A and celecoxib and NLT 1.8 between celecoxib and celecoxib related compound B, System suitability solution
Signal-to-noise ratio:  NLT 20, Standard solution
Analysis  
Samples:  Standard solution and Sample solution
Calculate the percentage of each impurity in the portion of Celecoxib taken:
Result = (rU/rS) ?? (CS/CU) ?? 100
rU = = peak response for each impurity in the Sample solution

rS = = peak response of celecoxib in the Standard solution

CS = = concentration of celecoxib in the Standard solution (mg/mL)

CU = = concentration of Celecoxib in the Sample solution (mg/mL)

Acceptance criteria  
Individual impurities:  See Table 1. [Note??Disregard any impurity peak less than 0.05%. ]
Table 1
Name Relative
Retention
Time Acceptance
Criteria,
NMT (%)
Celecoxib related compound Aa  0.9  0.4
Celecoxib  1.0  ??
Celecoxib related compound Bb  1.1  0.10
Individual unspecified impurity  ??  0.10
Total impurities  ??  0.5
a  4-[5-(3-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.
b  4-[3-(4-Methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.  

SPECIFIC TESTS
  Water Determination, Method I 921: NMT 0.5%, using a 400-mg sample
ADDITIONAL REQUIREMENTS
  Packaging and Storage: Preserve in tight containers, protected from light and moisture. Store at room temperature.
  USP Reference Standards 11
USP Celecoxib RS  
p-[5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide.
    C17H14F3N3O2S         381.4
USP Celecoxib Related Compound A RS  
4-[5-(3-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.
    C17H14F3N3O2S        381.4
USP Celecoxib Related Compound B RS  
4-[3-(4-Methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.
    C17H14F3N3O2S        381.4
Auxiliary Information?? Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph  Hillary Z Cai
Scientific Liaison, Small Molecules
(301) 230-3379  (SM22010) Monographs - Small Molecules 2
Reference Standards  RS Technical Services
1-301-816-8129
rstech@usp.org   

USP37?CNF32 Page 2246
Pharmacopeial Forum: Volume No. 36(6) Page 1519
Chromatographic Column??  
CELECOXIB
Chromatographic columns text is not derived from, and not part of, USP 37 or NF 32.
µ­²´Ã÷Ö¾£¬Äþ¾²ÖÂÔ¶
2Â¥2013-12-25 15:56:00
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

kobeyy

½ð³æ (ÕýʽдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

PF LGS# Brand Type of Test Additional Information
36(6)   L11  Supelcosil LC-DP  Assay and Organic Impurities  4.6 mm x 25 cm, 5 ??.
µ­²´Ã÷Ö¾£¬Äþ¾²ÖÂÔ¶
3Â¥2013-12-25 15:56:36
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ÔỨ¹«×Ó µÄÖ÷Ìâ¸üÐÂ
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û